System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Arnon P Kater is an expert in Hematology at Amsterdam University Medical Center (Netherlands). As of October 2026, ScienceLeadR ranks Arnon P Kater in the top 1% of experts worldwide for Leukemia and Lymphoproliferative Disorders. Arnon P Kater has authored 460 publications, the most recent in 2026, and is an investigator in 23 clinical trials, 3 of them ongoing. SLR score: 2,336 (community average: 125). How the SLR is computed.

LeadR Profile

Arnon P Kater Amsterdam University Medical Center Netherlands
2 336 ScienceLeadR Reputation 2336

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1999 - 2026
Source: PubMed

Amsterdam University Medical Center

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 460

Citations

Citations: 14 585 1st author: 66 Last author: 100 Unique author: 3

Main journals

Blood 163
Hemasphere 40
Leukemia 26
J Clin Oncol 17
Haematologica 16

Best Journals

J Clin Oncol 10
N Engl J Med 8
Lancet Oncol 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Pirtobrutinib for the Treatment of Therapy-Resistant Chronic Lymphatic Leukemia With CNS Localization.
PMID 42903336 — leukemia, lymphocytic, chronic, b-cell, leukemia, therapeutics		Case Rep Hematol20260
Correction: Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.
PMID 42888203 — leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid		Leukemia20260
Response to two comments on "EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation" by S. Molica and A. Tedeschi: Beyond the binary choice.
PMID 42852072 — leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid		Hemasphere20260
Telomere length in chronic lymphocytic leukemia treated with venetoclax-based regimen in GAIA/CLL13 and CLL2-GIVe trials.
PMID 42837320 — hematology, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, lymph, therapeutics, telomere		Blood20260
First-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survival.
PMID 42827117 — disease-free survival, progression-free survival, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, drug-related side effects and adverse reactions, chlorambucil, therapeutics		Leukemia20260

Clinical Studies 23

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 10
Phase 2 9
Phase 1/Phase 2 2
Phase 1 1
Phase 2/Phase 3 1

By status:

Completed 10
Active not recruiting 8
Recruiting 4
Unknown 1

By type:

Interventional 23

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 2
multicentric5to9 1
multicentricup10 20

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of BGB 16673 Compared to Investigator s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors
2024-518893-15-00 — lymphoma, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, rituximab, retreatment		Phase 3Recruiting2025
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
NCT05791409 — lymphoma, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, therapeutics, epcoritamab		Phase 1/Phase 2Recruiting2024
Ibrutinib Monotherapy Versus Fixed duration Venetoclax Plus Obinutuzumab Versus Fixed duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
NCT04608318 — cells, leukemia, leukemia, lymphoid, b-lymphocytes, leukemia, b-cell		Phase 3Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS